The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …

PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …

Background Epidermal growth factor receptor (EGFR) mutation represents a good response
to EGFR-tyrosine kinase inhibitor and an advantageous prognostic factor in advanced-stage …

In advanced nonsmall cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) is a major therapeutic target. Activating EGFR mutations, including either an in …

Introduction This study was to assess the association of epidermal growth factor receptor
(EGFR) mutation status and efficacy of adjuvant chemotherapy in patients with fully resected …

The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …

7519 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
show great efficacy in patients with advanced non-small cell lung cancer (NSCLC) with …

Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …

8016 Background: The first-line combination of an epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) plus platinum-based doublet chemotherapy has yet to be …